作者: Thomas R. Muley , Philipp A. Schnabel , Hendrik Dienemann , Felix Jf. Herth , Michael Meister
DOI: 10.3978/J.ISSN.2218-6751.2011.12.07
关键词:
摘要: Lung cancer is a leading cause of tumor-related death worldwide through years. Efforts to individualize lung therapy improve prognosis nowadays employ molecular analyses besides routine histopathological examination tissue samples. In general, tissues are provided by bronchoscopy, CT-guided procedures or surgery. The sequence removal, storage, and processing has considerable impact on the success reliability subsequent biological will supposedly also influence therapeutic decisions. There still an ongoing need for updated statements about minimal requirements sampling diagnosis at international level certified/accredited quality control programs procedures. Several these issues may have be adjusted individual local conditions. We present several aspects experiences gained in Thoraxklinik University Hospital Heidelberg (TK-HD) with pre-analytical requirements.